Listed

Enveric Biosciences, Inc.: Form 10-K/A for the period ended Dec 31, 2019

Filed with the SEC on Aug 12, 2020 and accepted by EDGAR at Aug 12, 2020, 17:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2019-01-01 to 2019-12-31$39.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2019-01-01 to 2019-12-31$31.8mus-gaap:CostOfRevenue
Gross profit12 months2019-01-01 to 2019-12-31$8.2mus-gaap:GrossProfit
Selling, general and administrative12 months2019-01-01 to 2019-12-31$12.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2019-01-01 to 2019-12-31−$6.3mus-gaap:OperatingIncomeLoss
Interest expense12 months2019-01-01 to 2019-12-31$694.9kus-gaap:InterestExpense
Income tax12 months2019-01-01 to 2019-12-31$388.7kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2019-01-01 to 2019-12-31−$5.6mus-gaap:NetIncomeLoss
Diluted EPS12 months2019-01-01 to 2019-12-31−$2.83us-gaap:EarningsPerShareDiluted
Basic EPS12 months2019-01-01 to 2019-12-31−$2.83us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2019-01-01 to 2019-12-312,128,806 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2019-01-01 to 2019-12-31−$2.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-12-31$431.4kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-12-31$7.6mus-gaap:AssetsCurrent
Total assetsAt period end2019-12-31$25.3mus-gaap:Assets
Current liabilitiesAt period end2019-12-31$14.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-12-31$14.7mus-gaap:Liabilities
Short-term borrowingsAt period end2019-12-31$4.9mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2019-12-31$10.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-20-015385. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.